BioCentury
ARTICLE | Clinical News

July 22 Clinical Quick Takes: Positive psoriasis data for Arcutis; plus Intec and Renovo

July 22, 2019 11:41 PM UTC

ARQ-151 meets Phase IIb endpoint
Arcutis Inc. (Westlake Village, Calif.) said high and low daily doses of ARQ-151 for six weeks met the primary endpoint in a Phase IIb trial of reducing signs of plaque psoriasis, measured via Investigator Global Assessment scores of clear or almost clear plaques, vs. vehicle (p<0.001 and p<0.004, respectively). The company plans to start a Phase III trial in 1Q20 of the topical reformulation of PDE-4 inhibitor roflumilast (see "Arcutis: Reformulating Dermatology").

Intec plummets after Phase III Parkinson's miss
Intec Pharma Ltd. (NASDAQ:NTEC) fell $2.44 (82%) to $0.55 Monday after reporting that Accordion Pill Carbidopa-Levodopa (AP-CD/LD) missed the primary endpoint of superiority to immediate release Sinemet levodopa/carbidopa from Merck & Co. Inc. (NYSE:MRK) in the Phase III ACCORDANCE trial to treat Parkinson's disease. The company said AP-CD/LD reduced PD symptoms and plans to analyze full data from ACCORDANCE's to determine next steps...